<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064553</url>
  </required_header>
  <id_info>
    <org_study_id>2021-01</org_study_id>
    <nct_id>NCT05064553</nct_id>
  </id_info>
  <brief_title>ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk</brief_title>
  <official_title>ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exact Sciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exact Sciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver&#xD;
      for hepatocellular cancer (HCC) detection in a surveillance population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects age 18 years and older who are at an increased risk for HCC and for whom HCC&#xD;
      surveillance is appropriate, including subjects with cirrhosis or non-cirrhotic subjects with&#xD;
      Hepatitis B. Approximately 3,000 subjects are expected to be enrolled, comprised of&#xD;
      approximately 2,222 ultrasound surveillance subjects and 778 subjects under surveillance with&#xD;
      CT/MRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of Oncoguard Liver in a HCC surveillance population</measure>
    <time_frame>A maximum of 30 days from study or standard-of-care CT or MRI exam.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of Oncoguard Liver in a HCC surveillance population</measure>
    <time_frame>A maximum of 30 days from study or standard-of-care CT or MRI exam.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of Oncoguard Liver among confirmed HCC subjects</measure>
    <time_frame>A maximum of 30 days from study or standard-of-care CT or MRI exam.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of Oncoguard Liver among confirmed non-HCC subjects</measure>
    <time_frame>A maximum of 30 days from study or standard-of-care CT or MRI exam.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early-stage sensitivity of Oncoguard Liver in a HCC surveillance population</measure>
    <time_frame>A maximum of 30 days from study or standard-of-care CT or MRI exam.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall and early-stage sensitivity as well as specificity of ultrasound</measure>
    <time_frame>Data collection will occur up to 8 months after the first Oncoguard Liver blood collection.</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatocellular Cancer</condition>
  <condition>Hepatitis B</condition>
  <condition>Cirrhosis</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Ultrasound Surveillance Group</arm_group_label>
    <description>Subjects will undergo standard of care ultrasound surveillance imaging. Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up with CT or MRI as well as other procedures as needed. Subjects with negative ultrasound will be sent for a study CT/MRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT/MRI Surveillance Group</arm_group_label>
    <description>Subjects will undergo standard of care CT/MRI surveillance imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Study CT/MRI Imaging</intervention_name>
    <description>Subjects with negative ultrasound will be sent for a study CT/MRI.</description>
    <arm_group_label>Ultrasound Surveillance Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard of Care CT/MRI Imaging</intervention_name>
    <description>Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up as well as other procedures as needed.</description>
    <arm_group_label>Ultrasound Surveillance Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Oncoguard Liver Test</intervention_name>
    <description>Subjects will have a blood sample collected for the Oncoguard Liver Test.</description>
    <arm_group_label>CT/MRI Surveillance Group</arm_group_label>
    <arm_group_label>Ultrasound Surveillance Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples derived from the blood collection may not be used in their entirety. Residual samples&#xD;
      may be archived indefinitely for further analysis and future research. Blood samples will be&#xD;
      labeled with unique codes containing letters and numbers.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects 18 years of age and older who are at an increased risk for HCC and for whom HCC&#xD;
        surveillance is appropriate, including subjects with cirrhosis and non-cirrhotic subjects&#xD;
        with Hepatitis B.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be 18 years of age or older.&#xD;
&#xD;
          2. Understand the study procedures, be able to provide written informed consent to&#xD;
             participate in the study, and have authorization for release of data, including&#xD;
             personal health data and images, to the study Investigator, Sponsor, and regulatory&#xD;
             authorities.&#xD;
&#xD;
          3. Present for surveillance imaging due to increased risk for HCC, including either:&#xD;
&#xD;
               1. Diagnosis of cirrhosis based on at least one of the following:&#xD;
&#xD;
                    -  Histology from a liver biopsy.&#xD;
&#xD;
                    -  Ultrasound, CT, or MRI showing a cirrhotic liver combined with portal&#xD;
                       hypertension (as evidenced by the presence of intra-abdominal varices, or&#xD;
                       recanalized umbilical vein, or ascites) and/or splenomegaly. The imaging&#xD;
                       results must have been obtained within 5 years of study enrollment.&#xD;
&#xD;
                    -  Liver stiffness ≥4.71 kilopascal (kPa) by Magnetic Resonance (MR)&#xD;
                       elastography or ≥12.1 kPa by vibration controlled transient elastography.&#xD;
&#xD;
                    -  Presence of varices on endoscopy or imaging and presence of a chronic liver&#xD;
                       disease. OR&#xD;
&#xD;
               2. Non-cirrhotic subjects with chronic Hepatitis B Virus (HBV) infection (Hepatitis&#xD;
                  B surface antigen present for &gt;6 months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known cancer diagnosis (including active malignancy) within the past 5 years except&#xD;
             for nonmelanoma skin cancer.&#xD;
&#xD;
          2. Chemotherapy and/or radiation therapy within 5 years prior to study enrollment.&#xD;
&#xD;
          3. Child-Pugh class C liver function at the time of enrollment, except for those on the&#xD;
             waiting list for transplant.&#xD;
&#xD;
          4. Solid liver nodule &gt;1 cm by ultrasound or elevated Alpha-fetoprotein (AFP) (&gt;100&#xD;
             ng/mL) in 12 months preceding the qualifying surveillance imaging visit without&#xD;
             subsequent documentation of HCC negative or LIRADS 1 (Liver Imaging Reporting and Data&#xD;
             System) by diagnostic CT/MRI.&#xD;
&#xD;
          5. Females known to be pregnant at the time of enrollment.&#xD;
&#xD;
          6. Illness that the Investigator believes poses a significant risk of mortality during&#xD;
             the study period, including but not limited to&#xD;
&#xD;
               1. Congestive heart failure with ejection fraction &lt;50%&#xD;
&#xD;
               2. Chronic lung disease requiring supplemental oxygen.&#xD;
&#xD;
               3. History of recent stroke.&#xD;
&#xD;
          7. Sustained virologic response (SVR) for Hepatitis C Virus (HCV) (undetectable HCV RNA&#xD;
             12 to 24 weeks after completion of antiviral therapy) for &gt;10 years prior to&#xD;
             enrollment.&#xD;
&#xD;
          8. Not able to have IV contrast for CT or MRI due to&#xD;
&#xD;
               1. Allergy to IV contrast and unwilling or unable to receive IV contrast after&#xD;
                  pre-medication.&#xD;
&#xD;
               2. Estimated glomerular filtration rate &lt;35 mL/min and not on hemodialysis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binu John</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami VA Healthcare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marla Kuleszynski, MS</last_name>
    <phone>608-400-3569</phone>
    <email>mkuleszynski@exactsciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caitlynne Nett</last_name>
    <phone>608-710-3930</phone>
    <email>cnett@exactsciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Franco Felizarta, MD</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecy Felizarta</last_name>
    </contact>
    <investigator>
      <last_name>Franco Felizarta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology &amp; Liver Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Olmos</last_name>
    </contact>
    <investigator>
      <last_name>Naveen Gara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manaf Alsudaney, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ju Dong Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>United Medical Doctors</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Luke</last_name>
    </contact>
    <investigator>
      <last_name>John Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Liver Research Institute</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misty Guillen</last_name>
    </contact>
    <investigator>
      <last_name>Edward Mena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Empire Clinical Trials</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Romo</last_name>
    </contact>
    <investigator>
      <last_name>Zeid Kayali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raydel Garcia</last_name>
    </contact>
    <investigator>
      <last_name>Idalia Acosta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Sagar</last_name>
    </contact>
    <investigator>
      <last_name>Huy Tran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Poche</last_name>
    </contact>
    <investigator>
      <last_name>Bal Raj Bhandari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana Research Center, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tricia Walker</last_name>
      <email>twalker@gis.md</email>
    </contact>
    <investigator>
      <last_name>Humberto Aguilar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research LLC (STAR)</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stormee White, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brian Borg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Berry, NP</last_name>
      <phone>901-309-6035</phone>
      <email>aberry@gastro1.com</email>
    </contact>
    <investigator>
      <last_name>Ziad Younes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flori Mantello</last_name>
    </contact>
    <investigator>
      <last_name>Harold Preiksaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Sample Collection</keyword>
  <keyword>CT/MRI</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Combined Hepatocellular and Cholangiocarcinoma</keyword>
  <keyword>HCC Surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in publications of the study will be shared after deidentification. This may include test, tables, figures, and appendices. The study protocol, statistical analysis plan (when applicable), informed consent form (when applicable), and the clinical study report (when applicable) will also be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be available from 2 years and ending 4 years after publication.</ipd_time_frame>
    <ipd_access_criteria>Proposals for access to data should be directed to clinicaltrials@exactsciences.com. To gain access, data requestors will need to provide a methodologically sound proposal and sign a data access agreement. Researchers are required to obtain necessary IRB/IEC approvals or waivers as applicable to conduct research.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

